ArQule to Report First Quarter 2010 Financial Results on May 6, 2010

WOBURN, Mass., Apr 29, 2010 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the first quarter of 2010 in a press release to be issued on Thursday, May 6, 2010 at 7:00 a.m. eastern time. The Company will host a conference call at 9:00 a.m. eastern time that day to discuss these results.

A replay of the conference call will be available beginning at Noon on May 6, 2010 for seven days and can be accessed by dialing toll-free (800) 642-1687 and outside the U.S. (706) 645-9291. The confirmation code for replayed calls is 70967314.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company is also conducting Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. The Company's pre-clinical pipeline includes a compound designed to inhibit the BRAF kinase. ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP(TM)), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase. These include a series of small molecule inhibitors of fibroblast growth factor receptor (FGFR).

SOURCE: ArQule, Inc.

ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
www.ArQule.com

Copyright Business Wire 2010

Close window | Back to top

• delicious
• Digg
• Facebook
• LinkedIn
• Mixx
• Twitter
• Yahoo! Buzz